Skip to search formSkip to main contentSkip to account menu

YN968D1

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

apatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review
ABSTRACT Up to now, no proven effective medical therapy for surgery and radiation-refractory anaplastic meningioma (AM) exists… 
2020
2020
Apatinib attenuates phenotypic switching of arterial smooth muscle cells in vascular remodelling by targeting the PDGF Receptor‐β
Apatinib (YN968D1) is a small‐molecule tyrosine kinase inhibitor（TKI）which can inhibit the activity of vascular endothelial… 
2019
2019
Immune-Mediated Antitumor Effect By VEGFR2 Selective Inhibitor For Gastric Cancer
Background It was previously reported that targeting vascular epithelial growth factor (VEGF)/VEGFR could modulate the antitumor… 
2018
2018
VEGFR2 Inhibitor YN968D1 Improves the T Cell-Mediated Cytotoxicity for Gastric Cancer
2017
2017
A phase I study to evaluate the pharmacokinetics of a new oncology nce, apatinib mesylate tablets, with and without food following single and multiple doses in healthy subjects.
e14049Background: Apatinib Mesylate (YN968D1) is a selective inhibitor of VEGFR-2 being developed for the treatment of advanced… 
2013
2013
Metabolism and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor Apatinib in Humans s
Apatinib is a new oral antiangiogenic molecule that inhibits vascular endothelial growth factor receptor-2. The present study… 
2010
2010
Cassette Transporters Inhibiting the Efflux Function of Multiple ATP-Binding Apatinib ( YN 968 D 1 ) Reverses Multidrug Resistance
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)